Background: Neoadjuvant chemotherapy is currently established as a standard therapeutic approach for patients with large (>2 cm) and locally advanced breast cancer. The histopathological evaluation of tumor response is the gold standard.

Methods: Histopathologic examination was done in 44 MRM specimen received in the department of pathology over a period of 1 year from August 2017 to July 2018.

Results: 44/44 cases are of female breast. Mean age of patient is 50 years. Mean size before CT was 56.14 cm² and after CT was 29.40 cm². In the present study 18% cases show complete pathologic response and 84% cases show incomplete response.

Conclusion: Characteristic pattern of changes observed after histopathological examination of tumor bed are cellular fibrous tissue, reactive lymphocytic infiltration, haemosiderin laden macrophages, areas of coagulative necrosis, stromal hyalinization, dystrophic calcification.

Keywords: Neoadjuvant chemotherapy, breast carcinoma, pathologic response.

1. Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol 2012; 23 Suppl 10: x231-6.
2. Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locore­gional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012; 30: 3960-6.
3. Carey LA, Metzger R, Dees EC,Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT,Graham ML (2005). American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97: 1137–42
4. Ogston KN, Miller ID, Payne S et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003;12:320–327
5. Abrial SC, Penault-Llorca F, Delva R, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005; 94: 255-63.
6. Pinder SE, Provenzano E, Earl H, Ellis IO. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 2007; 50: 409-17.
7. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414–4422
8. Penault-Llorca F, Abrial C, Raoelfils I et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol 2008;39:1221–1228
9. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001;7:3025-30.
10. Wang et al.: Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors. World Journal of Surgical Oncology 2013 11:166
11. Chakrabarti S, Mandal PK, Chowdhury AR, Das S.et al Consequence of neo-adjuvant chemotherapy on morphology of breast carcinoma: A systematic evaluation. Indian J Cancer 2016;53:29-33.
12. Ramana Kumari P, Sivarama Krishna TV, NagaKishore MG.et al Cytomorphological changes in breast carcinomas, after neoadjuvant chemotherapy: a study of twenty cases. Int J Res Med Sci 2015;3:3326-30
13. Dhanya Vasudevan,P. S. Jayalakshmy, Suresh Kumar, and Siji Mathew Assessment of Pathological Response of Breast Carcinoma in Modified Radical Mastectomy Specimens after Neoadjuvant Chemoth-erapy International Journal of Breast Cancer Volume 2015, Article ID 536145, 8 pages
14. Narendra H, Thomas J, Ray S, Fernandes DJ et al  An analysis of response to neo‑adjuvant chemotherapy in patients with locally advanced breast cancer with emphasis on pathological complete response, Indian Journal of Cancer | October–December 2014 | Volume 51 | Issue 4
15. S Baulies, L Belin , P Mallon, C Senechal, J-Y Pierga , P Cottu , M-P Sablin , X Sastre, B Asselain , R Rouzier and F Reyal et al, Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy British Journal of Cancer (2015) 113, 30–36.
16. Siregar KB, Pane J, Siburian R. Et alCorrelation between Tumor-Infiltrating Lymphocytes and Pathological Response in Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapyin H. Adam Malik General Hospital. Case Rep Oncol. 2017 Aug 4;10 (2):699-705. doi: 10.1159/000477799. eCollection 2017 May-Aug)
17. Anne-Sophie Hamy-Petit , Lisa Belin , He´ le` ne Bonsang-Kitzis, Caroline Paquet , Jean-Yves Pierga , Florence Lerebours, Paul Cottu , Roman Rouzier , Alexia Savignoni , Marick Lae and Fabien Reyal et al Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort British Journal of Cancer (2016) 114, 44–52
18. Jung YY, Hyun CL, Jin MS, Park IA, Chung YR, Shim B, Lee KH, Ryu HS. et al Histomorphological Factors Predicting the Responseto Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. J Breast Cancer. 2016 Sep; 19(3):261-267. Epub 2016 Sep 23.
19. Pu RT, Schott AF, Sturtz DE, Griffith KA, Kleer CG.et al Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis Am J Surg Pathol. 2005 Mar;29(3):354-8.

20. Honkop AH, Pinedo HM, Dejong JS, et al. Effects of chemotherapy on pathological characteristics of locally advanced breast cancer. Am J Clin Pathol 1997;107:211-218.

Dr Sandhya Verma

Address- R-11, Street no. 3, Dubey colony, Mowa Raipur Pin Code:492007, India

Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Mobile no.- 9755227113